Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

May 29, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called spinocerebellar ataxia. Read more here.

In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.47 per share. By comparison ...

In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease. The FDA’s Decision on BHVN’s Drug Candidate The FDA agreed to review BHVN ...